Remember that it takes nine months to show regression. From first enrollment to data presentation it will take two years and then first drug sold would be six months after that. With that being said, if the data is good enough from P2 then the FDA can designate it with a Fast Track...
Two conference calls.
8:30am ET: Talk about new best friend
5:00 ET: Talk about previous quarter and how they are going to make even more best friends.
Does it matter? The upfront payment is negligible if we are talking 775million in milestone payments and 35% profits for many years to come. I mean if Afrezza hits 1b in sales then that's 350m in revenue a year for many years. Now we just have to talk about that pesky technospere technology.... That's where the real money is at.
You take the outstanding shares and multiply it by the stock price to get the companies market cap. That being said it doesn't take much of an investor to figure it out. Not sure why you have to read a street article to figure it out. By the way price is what you pay, value is what you get. I will let you soak on that for a while.
I think it would be very neat to show a profit so soon. That being said, I fully trust we will continue to see robust growth that's exponential rather than linear. A final point is that, if one day Exparel becomes a SOC we will need to reevaluate or long term forecasts.
The float is very small, so if you increase the amount of shares out there on the open market, you will have more buyers and sellers. As for institutions or hedges, there might be pre-negotiated deals they might offer 15 million shares for like 11 a share.
To pay for P3 trial, increase trading activity. Allow more institutions to buy more stock. Raise capital with out increasing debt. Allow for a partner to join in the fun. This is a high stakes game of chess, I trust that Dr. Kim had this planned out.
It will my 3rd as well and the reverse split. But remember the S-3 last year for 2.90 when the stock was trading at 3.95, it gave us a good baseline for a while.
Hey Ino longs I just put 2 and 2 together, there will be some dillution coming in the fomr of 175 Million, that should be enough to cover the P3 expenses unless another Pharma wants to take that burden... just saying.
Virological clearance of HPV 16 or 18 from the cervix in conjunction with histopathological regression of cervical dysplasia to CIN1 or no disease, a secondary endpoint of the trial, was observed in 43 of 107 (40.2%) VGX-3100 recipients compared to 5 of 35 (14.3%) placebo recipients (p
We want breakthrough status... it speeds up the entire process, Orphan just means it is a really rare disease, HPV is relatively speaking pretty common. However their are no cures for it... hints we want breakthrough status.